因与果：病因学与药学携手共进改善健康
代表会议的主办方， 我们盛情邀请您来参加2015年4月10日至12日在中国上海国际会议中心举办的第7届亚洲肿瘤峰会和第11届肿瘤与转化研究组织年会。
病毒性肝炎专题峰会也将首次同时举行，此次峰会将聚集来自各个学科的专家，为共同研究、促进合作提供了独一无二的机会。 您可以在这里下载本次会议的日程安排。
我们同时邀请您来参与简短发言交流及海报演讲，参与人请于2015年1月26日之前提交会议演讲摘要。演讲议题内容如下：
肿瘤学议题：预防、姑息治疗、胃肠癌、乳腺癌、泌尿系统肿瘤、肺癌、转化肿瘤学、血液肿瘤学、支持性肿瘤学、黑色素瘤、肉瘤、头颈部肿瘤、健康经济学、放射肿瘤学、妇科肿瘤、药物经济学、医疗护理服务、分子病理学以及癌症治疗内分泌晚期效应。
病毒性肝炎议题： 乙型肝炎、丙型肝炎、戊型肝炎和甲型肝炎的治疗与预防，以及病毒癌变机理。 您可以在这里提交摘要。
我们相信这个独一无二的会议－加上您的积极参与－将会启发亚洲医学实践与研究的未来发展方向。于2015年2月6日前预订参会的代表将可获得入场费优惠折扣，同时本次会议的赞助支持协会的会员也将获得优惠。 您可以在这里注册参加亚洲肿瘤峰会及病毒性肝炎专题2015。
我们期待与您在上海会面。
Rob Brierley
AOS 2015峰会主持，The Lancet Oncology期刊副主编
Louis Chow
第11届OOTR年会主持，OOTR执行总监
Masakazu Toi
第11届OOTR年会主持，OOTR主席
John McConnell
病毒性肝炎2015主持，Lancet Infectious Diseases主编
Ching-Lung Lai
病毒性肝炎2015联合主持，香港大学，香港
Michael Manns
病毒性肝炎2015联合主持，汉诺威医学院，德国
April 11, Saturday
0955 - 1020
Discovery of the HBV receptor: impact for prophylaxis and therapy - Wenhui Li (China)
1530 - 1555
Hepatitis B cure: the new challenge in hepatitis B therapy
- Fabien Zoulim (France)作者: StephenW 时间: 2015-4-11 14:09
本帖最后由 StephenW 于 2015-4-11 14:11 编辑
Replicor to Present at the 2015 Lancet Viral Hepatitis Conference
April 10, 2015 06:00 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated clinical data at the Lancet Viral Hepatitis Conference in Shanghai, China from April 10-12, 2015. The data are from studies involving patients with chronic HBV infection who were treated with REP 2139-Ca in combination with immunotherapy and /or entecavir (ETV).
REP 2139-Ca used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV was safe and well-tolerated and resulted in an antiviral response that was profound and includes: the elimination (up to 7 log reduction to LLOQ) of HBsAg in the blood seroconversion for both HBsAg and HBeAg and, the elimination (up to 6 log reduction to LLOQ) of serum HBV DNA. These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.
Contacts
Effects of nucleic acid polymer therapy alone or in
combination with immunotherapy on the establishment of
SVR in patients with chronic HBV infection.
Mamun-Al-Mahtab1, Michel Bazinet2and Andrew Vaillant2
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh,
2Replicor Inc., Montreal, Canada H8Y 3E6
单独或效果的核酸聚合物疗法
关于建立与免疫相结合
SVR与慢性HBV感染。
马蒙 - 铝 - Mahtab1，米歇尔Bazinet2and安德鲁Vaillant2
1Bangabandhu谢赫穆吉布医科大学，孟加拉国达卡，
2Replicor公司，加拿大蒙特利尔H8Y3E6
